Vor Biopharma Inc. (VOR) SEC Filings & Earnings Calls

Warrant liability volatility

“Warrant liabilities $ 653,894 (June 30, 2026); Change in fair value of warrant liabilities $ (207,657) (six months ended June 30, 2026).”

No revenue and ongoing losses

“We have incurred significant net losses since inception. We expect to incur net losses for the foreseeable future and may never achieve or maintain profitability.” · word for word

Dependence on telitacicept

“We are substantially dependent on the success of our lead product candidate, telitacicept.” · word for word

No material risk from board change; standard compensation and no disagreement.

“Resignation not due to any disagreement; new director has relevant pharma leadership experience.”

Approval is conditional and in China only; Vor Bio's rights are ex-Greater China. Global regulatory path still uncertain.

“Conditional approval in China; Vor Bio responsible for development outside Greater China.”

Clinical trial failure risk

“We are substantially dependent on the success of our lead product candidate, telitacicept.” · word for word

Funding dependency

“We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.” · word for word

Warrant liability volatility

“Change in fair value of warrant liabilities (188,360) — Total other (expense) income (184,425)” · word for word

Activist/insider selling pressure

“Open Market Sale Fund 04/13/2026 530,610 16.15 15.94 16.32 Open Market Sale Fund 04/14/2026 153,735 15.97 15.75 16.17 Open Market Sale Fund 04/15/2026 53,644 16.01 16.005 16.10” · word for word

Activist/insider selling pressure

“Open Market Sale Fund 04/13/2026 530,610 16.15 15.94 16.32 Open Market Sale Fund 04/14/2026 153,735 15.97 15.75 16.17 Open Market Sale Fund 04/15/2026 53,644 16.01 16.005 16.10” · word for word

Activist/insider selling pressure

“RA Capital sold 620,133 shares in open market transactions April 8-10, 2026.”

Activist/insider selling pressure

“RA Capital sold 620,133 shares in open market transactions April 8-10, 2026.”

Activist/insider selling pressure

“RA Capital Healthcare Fund sold 849,232 shares in open market transactions between April 2 and April 6, 2026, at prices ranging from $16.25 to $19.09 per share”

Activist/insider selling pressure

“RA Capital Healthcare Fund sold 849,232 shares in open market transactions between April 2 and April 6, 2026, at prices ranging from $16.25 to $19.09 per share”

Clinical trial failure risk

“We are substantially dependent on the success of our lead product candidate, telitacicept. If we are unable to complete development of, obtain approval for and commercialize telitacicept in a timely manner, our business will be harmed.” · word for word

Financing risk

“We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.” · word for word

Dependence on third-party data

“We may derive results and data for telitacicept from clinical trials conducted by RemeGen in China; our access to the clinical results and data may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities.” · word for word

Intellectual property risk

“We are highly dependent on intellectual property licensed from third parties and termination of these licenses could result in the loss of significant rights, which would harm our business.” · word for word

Competition risk

“We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours.” · word for word

Dilution risk; reliance on equity financing for pipeline; no revenue disclosed.

“5.34M new shares; pre-revenue biotech; proceeds for pipeline development.”

Pre-revenue biotech with no approved products in US/EU; clinical and regulatory risks.

“No revenue or earnings guidance; pipeline dependency on telitacicept.”

Preliminary cash balance subject to audit adjustment.

“The cash, cash equivalents and short-term investments information above... is preliminary, has not been audited and is subject to change” · word for word

Loss of key development officer may impact pipeline progress; consulting arrangement mitigates near-term risk.

“Dr. Zuraw's departure; consulting arrangement for Q1 2026 transition.”

Dilution risk from issuance of 13.9M new shares.

“Issuance of 13,876,032 shares in private placement.”

Stock price decline indicated by option repricing; potential dilution if exercised

“Options repriced from $17.80-$47.60 to $8.18; 5.2M shares affected”

Substantial doubt about going concern / need for additional funding

“We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our research and product development programs or future commercialization efforts.” · word for word

Dependence on single product candidate telitacicept

“We are substantially dependent on the success of our lead product candidate, telitacicept. If we are unable to complete development of, obtain approval for and commercialize telitacicept in a timely manner, our business will be harmed.” · word for word

Massive warrant liability and potential dilution

“The remaining 48,854,170 outstanding 2025 Warrants have a fair value of $2,380.1 million as of September 30, 2025.” · word for word

Reliance on third-party data from RemeGen

“We may derive results and data for telitacicept from clinical trials conducted by RemeGen in China; our access to the clinical results and data may be limited and there is no assurance that the clinical data from any such trials will be accepted or considered by the FDA, or other comparable regulatory authorities.” · word for word

Dilution risk from equity offering.

“Equity offering via underwriting agreement.”

No financial metrics or guidance provided; clinical-stage company with no approved products.

“Clinical-stage biotechnology company; no revenue mentioned.”

Clinical trial data from China; regulatory approval and commercialization risks remain.

“Data from China Phase 3 trial; forward-looking statements highlight uncertainties in regulatory approvals and commercialization.”